Julie Ann Taylor

US Patent:

7807167, Oct 5, 2010

Filed:

Oct 2, 2006

Appl. No.:

11/540640

Inventors:

Julie Taylor - San Francisco CA, US
Theodore A. Yednock - Forest Knolls CA, US

Assignee:

Elan Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

A61K 39/395

US Classification:

4241431, 4241441, 4241521

Abstract:

A method of chronically reducing a patient's pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the agent is administered chronically to provide long-term suppression of pathological inflammation.

US Patent:

8124350, Feb 28, 2012

Filed:

Apr 4, 2006

Appl. No.:

11/887782

Inventors:

Meena Subramanyam - Stoneham MA, US
Lakshmi Amaravadi - Natick MA, US
Eric Wakshull - Princeton MA, US
Frances Lynn - Somerville MA, US
Michael Panzara - Winchester MA, US
Robin Mcdaid Barbour - Walnut Creek CA, US
Julie Elizabeth Taylor - San Francisco CA, US

Assignee:

Biogen Idec MA Inc. - Cambridge MA
Elan Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

G01N 33/53
G01N 33/541
G01N 33/577

US Classification:

435 71, 435 792, 435 793, 435 794

Abstract:

The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. A first aspect of the invention relates to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e. g. , natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titre of antibodies against the therapeutic protein, e. g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titre of untreated patients increased by the double of the standard deviation of this control antibody titre.

US Patent:

20040009169, Jan 15, 2004

Filed:

Feb 25, 2003

Appl. No.:

10/372111

Inventors:

Julie Taylor - San Francisco CA, US
Theodore Yednock - Forest Knolls CA, US

International Classification:

A61K039/395

US Classification:

424/144100

Abstract:

A method of chronically reducing a patient's pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the agent is administered chronically to provide long-term suppression of pathological inflammation.

US Patent:

20110064729, Mar 17, 2011

Filed:

Jul 29, 2010

Appl. No.:

12/846350

Inventors:

Julie TAYLOR - San Francisco CA, US
Theodore A. Yednock - Forest Knolls CA, US

Assignee:

Elan Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

A61K 39/395
A61P 1/00
A61P 29/00
A61P 1/04

US Classification:

4241331

Abstract:

A method of chronically reducing a patient's pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the agent is administered chronically to provide long-term suppression of pathological inflammation.

US Patent:

20120195884, Aug 2, 2012

Filed:

Sep 23, 2011

Appl. No.:

13/242505

Inventors:

Meena Subramanyam - Stoneham MA, US
Lakshmi Amaravadi - Natick MA, US
Eric Wakshull - Princeton MA, US
Frances Lynn - Somerville MA, US
Michael Panzara - Winchester MA, US
Robin Mcdaid Barbour - Walnut Creek CA, US
Julie Elizabeth Taylor - San Francisco CA, US

Assignee:

Biogen Idec MA Inc. - Cambridge MA
Elan Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

A61K 39/395
G01N 33/566
A61P 37/00
C07K 16/42

US Classification:

4241331, 5303872, 435 792

Abstract:

The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titre of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titre of untreated patients increased by the double of the standard deviation of this control antibody titre.

US Patent:

20210025900, Jan 28, 2021

Filed:

Jul 7, 2020

Appl. No.:

16/923043

Inventors:

- Cambridge MA, US
Lakshimi Amaravadi - Natick MA, US
Eric Wakshull - Princeton MA, US
Frances Lynn - Somerville MA, US
Michael Panzara - Winchester MA, US
Robin McDaid Barbour - Walnut Creek CA, US
Julie Elizabeth Taylor - San Francisco CA, US

International Classification:

G01N 33/68
C07K 16/28

Abstract:

The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).

US Patent:

20180088127, Mar 29, 2018

Filed:

Jun 7, 2017

Appl. No.:

15/616669

Inventors:

- Cambridge MA, US
Lakshmi Amaravadi - Natick MA, US
Eric Wakshull - Princeton MA, US
Frances Lynn - Somerville MA, US
Michael Panzara - Winchester MA, US
Robin McDaid Barbour - Walnut Creek CA, US
Julie Elizabeth Taylor - San Francisco CA, US

Assignee:

Biogen MA Inc. - Cambridge MA

International Classification:

G01N 33/68
C07K 16/28

Abstract:

The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).

US Patent:

20150071917, Mar 12, 2015

Filed:

Jul 14, 2014

Appl. No.:

14/330619

Inventors:

- Cambridge MA, US
Lakshmi Amaravadi - Natick MA, US
Eric Wakshull - Princeton MA, US
Frances Lynn - Somerville MA, US
Michael Panzara - Winchester MA, US
Robin McDaid Barbour - Walnut Creek CA, US
Julie Elizabeth Taylor - San Francisco CA, US

Assignee:

Biogen Idec MA Inc. - Cambridge MA

International Classification:

G01N 33/68
C07K 16/28

US Classification:

4241331, 435 792

Abstract:

The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. A first aspect of the invention relates to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titre of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titre of untreated patients increased by the double of the standard deviation of this control antibody titre.